Abstract:
Cannabidiol (CBD) is part of a group of more than 100 molecules named
phytocannabinoids. This molecule can cross the blood-brain barrier due to its lipid
profile, and it is considered the most common phytocannabinoid in the Cannabis
sativa. CBD has been studied as a therapeutic alternative for the treatment of
neurological diseases, showing promising results in different studies. This work aimed to detail the pharmacology of CBD in the face of neuropathologies through an
integrative review of the literature. CBD has been used in different neurological
disorders such as Alzheimer's, neurological pain, autism spectrum, Parkinson's,
epilepsy, and some other disorders. The main mechanism of action of CBD in the
CNS is related to the interaction with the endocannabinoid system, which is
responsible for the body's homeostasis and also for its ability to act as a
neurotransmitter modulator. Therefore, it was possible to demonstrate that the use of
CBD is a plausible alternative to enhance the treatment of neuropathologies, due to
its positive results in the treatment of these comorbidities.
Keywords: cannabis sativa, neuropathologies, pharmacists, mechanism of action,
legislation.
